Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 16

1.

A cardiovascular phenotype in warfarin-resistant Vkorc1 mutant rats.

Kohn MH, Price RE, Pelz HJ.

Artery Res. 2008 Nov;2(4):138-147.

2.

Analysis of vkorc1 polymorphisms in Norway rats using the roof rat as outgroup.

Díaz JC, Song Y, Moore A, Borchert JN, Kohn MH.

BMC Genet. 2010 May 24;11:43. doi: 10.1186/1471-2156-11-43.

4.

VKORC1 gene (vitamin K epoxide reductase) polymorphisms are associated with cardiovascular disease in chronic kidney disease patients on hemodialysis.

Osman NA, El-Abd N, Nasrallah M.

Saudi J Kidney Dis Transpl. 2016 Sep-Oct;27(5):908-915. doi: 10.4103/1319-2442.190782.

5.

New insights into the catalytic mechanism of vitamin K epoxide reductase (VKORC1) - The catalytic properties of the major mutations of rVKORC1 explain the biological cost associated to mutations.

Matagrin B, Hodroge A, Montagut-Romans A, Andru J, Fourel I, Besse S, Benoit E, Lattard V.

FEBS Open Bio. 2013 Feb 16;3:144-50. doi: 10.1016/j.fob.2013.02.001.

6.

VKORC1 polymorphisms and warfarin maintenance dose in population of Sakha (Yakuts).

Chertovskikh YV, Malova EU, Maksimova NR, Popova NV, Sychev DA.

Int J Risk Saf Med. 2015;27 Suppl 1:S17-8. doi: 10.3233/JRS-150673.

PMID:
26639691
7.

Reviews of Selected Pharmacogenetic Tests for Non-Cancer and Cancer Conditions [Internet].

Raman G, Trikalinos TA, Zintzaras E, Kitsios G, Ziogas D, Ip S, Lau J.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2008 Nov 12.

8.

VKCFD2 - from clinical phenotype to molecular mechanism.

Czogalla KJ, Watzka M, Oldenburg J.

Hamostaseologie. 2016 Nov 8;36(Suppl. 2):S13-S20.

PMID:
27824210
9.
10.

Vitamin K epoxide reductase complex subunit 1 (Vkorc1) haplotype diversity in mouse priority strains.

Song Y, Vera N, Kohn MH.

BMC Res Notes. 2008 Dec 1;1:125. doi: 10.1186/1756-0500-1-125.

11.

Linkage disequilibrium between the CYP2C19*2,*17 and CYP2C9*1 alleles and impact of VKORC1, CYP2C9, CYP2C19 gene polymorphisms and gene-gene interactions on warfarin therapy.

Khalighi K, Cheng G, Mirabbasi S, Khalighi B, Wu Y, Fan W.

J Thromb Thrombolysis. 2016 Oct 14. [Epub ahead of print]

PMID:
27743182
12.

The effect of CYP2C9 and VKORC1 genetic polymorphisms on warfarin dose requirements in a pediatric population.

Dilge Taşkın B, Kula S, Ergün MA, Altun D, Olguntürk R, Tunaoğlu FS, Oğuz AD, Gürsel T.

Anatol J Cardiol. 2016 Jan 25. doi: 10.14744/AnatolJCardiol.2015.6150. [Epub ahead of print]

13.

Warfarin-resistance genotype determination in the Norway rat, Rattus norvegicus.

Martin AD, Steed LC, Redfern R, Gill JE, Huson LW.

Lab Anim. 1979 Jul;13(3):209-14.

PMID:
553191
14.

Genetic variation and haplotype structure of the gene Vitamin K epoxide reductase complex, subunit 1 in the Tamilian population.

Kumar DK, Shewade DG, Surendiran A, Adithan C.

J Pharmacol Pharmacother. 2013 Jan;4(1):53-8. doi: 10.4103/0976-500X.107683.

15.

Factors affecting the interindividual variability of warfarin dose requirement in adult Korean patients.

Cho HJ, Sohn KH, Park HM, Lee KH, Choi B, Kim S, Kim JS, On YK, Chun MR, Kim HJ, Kim JW, Lee SY.

Pharmacogenomics. 2007 Apr;8(4):329-37.

PMID:
17391071
Items per page

Supplemental Content

Support Center